EconPapers has moved to http://EconPapers.repec.org! Please update your bookmarks.
PharmacoEconomics
1998 - 2012
Edited by Christopher I. Carswell, MSc, MRPharmS
from Springer Healthcare | Adis
Access Statistics for this journal.
RSS feed
Is something missing from the series or not right? See the RePEc data check for the archive and series .
Volume 29, issue 12 , 2011
Acknowledgement pp. 1011-1013 Adis International Limited Erratum pp. 1014 Adis International Limited QALYs and Carers pp. 1015-1023 Hareth Al-Janabi , Terry Flynn and Joanna Coast Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: A Methodological Review pp. 1025-1049 Judith Dams , Bernhard Bornschein , Jens Peter Reese , Annette Conrads-Frank , Wolfgang Oertel , Uwe Siebert and Richard Dodel Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy: A NICE Single Technology Appraisal pp. 1051-1062 Rumona Dickson , Adrian Bagust , Angela Boland , Michaela Blundell , Helen Davis , Yenal Dundar , Juliet Hockenhull , Carlos Martin Saborido , James Oyee and Vidhya Ramani Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection pp. 1063-1073 Hui-Fang Hung and Hsiu-Hsi Chen Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective pp. 1075-1091 Helen Dakin , Morris Sherman , Scott Fung , Carrie Fidler and Anthony Bentley Volume 29, issue 11 , 2011
The Importance of the Comparator in Economic Evaluations: Working on the Efficiency Frontier pp. 913-916 Mattias Neyt and Hans Van Brabandt Utility Estimation in Chronic Obstructive Pulmonary Disease: A Preference for Change? pp. 917-932 Jennifer Petrillo , Floortje van Nooten , Paul Jones and Maureen Rutten-van Molken Sample Size Determination for Cost-Effectiveness Trials pp. 933-949 Andrew Willan Denosumab for the Prevention of Osteoporotic Fractures in Post-Menopausal Women: A NICE Single Technology Appraisal pp. 951-961 Graham Scotland , Norman Waugh , Pamela Royle , Paul McNamee , Rob Henderson and Rosemary Hollick Willingness to Pay for Adverse Drug Event Regulatory Actions pp. 963-975 Jacoline Bouvy , Just Weemers , Huub Schellekens and Marc Koopmanschap Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma pp. 977-988 Ateesha Mohamed , A. Hauber and Maureen Neary Rotavirus Vaccine RIX4414 (Rotarix™): A Pharmacoeconomic Review of its Use in the Prevention of Rotavirus Gastroenteritis in Developing Countries pp. 989-1009 Greg Plosker Volume 29, issue 10 , 2011
Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions: The Case for Reference Models pp. 823-825 Hossein Haji Ali Afzali and Jonathan Karnon Cautions Regarding the Fitting and Interpretation of Survival Curves: Examples from NICE Single Technology Appraisals of Drugs for Cancer pp. 827-837 Martin Connock , Chris Hyde and David Moore A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease: Implications for Policy pp. 839-861 Joseph Menzin , Lisa Lines , Daniel Weiner , Peter Neumann , Christine Nichols , Lauren Rodriguez , Irene Agodoa and Tracy Mayne Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer: A Systematic Review of the Literature pp. 863-874 Gery GuyJr and Donatus Ekwueme Does the Market Share of Generic Medicines Influence the Price Level?: A European Analysis pp. 875-882 Pieter Dylst and Steven Simoens Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs pp. 883-893 Alain Denis , Lut Mergaert , Christel Fostier , Irina Cleemput , Frank Hulstaert and Steven Simoens Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium pp. 895-911 Mickael Hiligsmann and Jean-Yves Reginster Volume 29, issue 9 , 2011
Value-Based Pricing: Incentive for Innovation or Zero Net Benefit? pp. 731-735 Dyfrig Hughes Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies: Reviewing the Available Evidence pp. 737-751 Petros Pechlivanoglou , Robin Vries , Simon Daenen and Maarten Postma Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure: A Systematic Review pp. 753-769 Alexander Goehler , Benjamin Geisler , Jennifer Manne , Beate Jahn , Annette Conrads-Frank , Petra Schnell-Inderst , G. Gazelle and Uwe Siebert To Fund or Not to Fund: Development of a Decision-Making Framework for the Coverage of New Health Technologies pp. 771-780 Tania Stafinski , Devidas Menon , Christopher Joseph McCabe and Donald Philippon Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand pp. 781-806 Naiyana Praditsitthikorn , Yot Teerawattananon , Sripen Tantivess , Supon Limwattananon , Arthorn Riewpaiboon , Saibua Chichareon , Nantakan Ieumwananonthachai and Viroj Tangcharoensathien Cinacalcet: A Pharmacoeconomic Review of its Use in Secondary Hyperparathyroidism in End-Stage Renal Disease pp. 807-821 Greg Plosker Volume 29, issue 8 , 2011
The Case for Less, Not More, US FDA Regulation pp. 637-640 John Vernon and Joseph Golec Challenges in Health State Valuation in Paediatric Economic Evaluation: Are QALYs Contraindicated? pp. 641-652 Wendy Ungar Cost-of-Illness Studies: A Guide to Critical Evaluation pp. 653-671 Allison Larg and John Moss Using QALYs in Cancer: A Review of the Methodological Limitations pp. 673-685 Martina Garau , Koonal K. Shah , Anne Rosemary Mason , Qing Wang , Adrian Towse and Michael Drummond US FDA Modernization Act, Section 114: Uses, Opportunities and Implications for Comparative Effectiveness Research pp. 687-692 Peter Neumann , Pei-Jung Lin and Tom Hughes Cost Estimation of Cardiovascular Disease Events in the US pp. 693-704 O'Sullivan, Amy , Jaime Rubin , Joshua Nyambose , Andreas Kuznik , David Cohen and David Thompson Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis: Focus on Critically Ill Patients pp. 705-717 Annette Reboli , Coleman Rotstein , Daniel Kett , Michael Maschio , Shannon Cartier , Richard Chambers and Miriam Tarallo Estimating the Relationship between Preference-Based Generic Utility Instruments and Disease-Specific Quality-of-Life Measures in Severe Chronic Constipation: Challenges in Practice pp. 719-730 Mark Parker , Alan Haycox and Jane Graves Volume 29, issue 7 , 2011
Reflections on the Changing Face of German Pharmaceutical Policy: How Far is Germany from Value-Based Pricing? pp. 549-553 Andreas Gerber , Stephanie Stock and Charalabos-Markos Dintsios Prioritizing Comparative Effectiveness Research: Are Drug and Implementation Trials Equally Worth Funding? pp. 555-561 Afschin Gandjour Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies pp. 563-577 Simon Eckermann and Andrew Willan Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV: A Systematic Review for Low- and Middle-Income Countries pp. 579-599 Omar Galárraga , Veronika Wirtz , Alejandro Figueroa-Lara , Yared Santa-Ana-Tellez , Ibrahima Coulibaly , Kirsi Viisainen , Antonieta Medina-Lara and Eline Korenromp Do Productivity Costs Matter?: The Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders pp. 601-619 Marieke Krol , Jocé Papenburg , Marc Koopmanschap and Werner B.F. Brouwer Medication Costs to Private Insurers of Diversion of Medications for Attention-Deficit Hyperactivity Disorder pp. 621-635 Arnie Aldridge , Larry Kroutil , Alexander Cowell , Daniel Reeves and David Van Brunt Volume 29, issue 6 , 2011
The Appropriate Elicitation of Expert Opinion in Economic Models: Making Expert Data Fit for Purpose pp. 455-459 William Sullivan and Katherine Payne Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US: A Literature Review pp. 461-474 Bin Zhang , Prina Donga , Mitra Corral , Medha Sasane , Jeffrey Miller and Chris Pashos Health Technology Funding Decision-Making Processes Around the World: The Same, Yet Different pp. 475-495 Tania Stafinski , Devidas Menon , Donald Philippon and Christopher Joseph McCabe A Discrete-Event Simulation of Smoking-Cessation Strategies Based on Varenicline Pivotal Trial Data pp. 497-510 James Xenakis , Elizabeth Kinter , K. Ishak , Alexandra Ward , Marton, Jenő , Richard Willke , Simon Davies and J. Caro The Direct Medical Costs Associated with Suspected Heparin-Induced Thrombocytopenia pp. 511-520 Natasha Nanwa , Nicole Mittmann , Sandra Knowles , Claudia Bucci , Rita Selby , Neil Shear , Scott Walker and William Geerts A Value Set for the EQ-5D Based on Experienced Health States: Development and Testing for the German Population pp. 521-534 Reiner Martin Leidl and Peter Reitmeir Intravenous Esomeprazole: A Pharmacoeconomic Profile of its Use in the Prevention of Recurrent Peptic Ulcer Bleeding pp. 535-543 Gillian Keating PAID 1.0 in Practice: A Brief Clarification Regarding its Possibilities and Limitations pp. 545-547 Pieter van Baal and Werner B.F. Brouwer Volume 29, issue 5 , 2011
Adjuvant Trastuzumab for Breast Cancer: Uncertainties in Clinical and Economic Evidence Following Early Stopping of the HERA Trial pp. 361-365 Tallal Younis and Chris Skedgel Health Economic and Infectious Disease Modelling: A Guide to Merging Streams pp. 367-369 Andrea Anonychuk and Murray Krahn Modelling the Epidemiology of Infectious Diseases for Decision Analysis: A Primer pp. 371-386 Mark Jit and Marc Brisson Cost Effectiveness of Treatments for Inflammatory Bowel Disease pp. 387-401 Keith Bodger Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease: Australian, Canadian and Swedish Healthcare Perspectives pp. 403-414 Nicole Mittmann , Paul Hernandez , Carl Mellstrom , Lance Brannman and Tobias Welte Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer: A UK Perspective Considering Duration of Benefit, Long-Term Toxicity and Pattern of Recurrence pp. 415-432 Peter Hall , Claire Hulme , Christopher Joseph McCabe , Yemi Oluboyede , Jeff Round and David Cameron Is There a Role for Pharmacoeconomics in Developing Countries? pp. 433-435 Román Pérez Velasco and Yot Teerawattananon Is There a Role for Pharmacoeconomics in Developing Countries? pp. 435-436 Jonathan Harper The Authors' Reply pp. 436-437 Zaheer-Ud-Din Babar and Shane Scahill Rotavirus Vaccine RIX4414 (Rotarix™): A Pharmacoeconomic Review of its Use in the Prevention of Rotavirus Gastroenteritis in Developed Countries pp. 439-454 Greg Plosker Volume 29, issue 4 , 2011
The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma: An Overview of Clinical and Economic Information pp. 269-285 Andrea Messori , Dario Maratea , Chiara Nozzoli and Alberto Bosi Sample Size and Power for Cost-Effectiveness Analysis (Part 2): The Effect of Maximum Willingness to Pay pp. 287-296 Henry Glick Sensitivity Analysis in Cost-Effectiveness Studies: From Guidelines to Practice pp. 297-314 Rahul Jain , Michael Grabner and Eberechukwu Onukwugha Economic Burden of Renal Cell Carcinoma: Part I - An Updated Review pp. 315-329 Ya-Chen Shih , Chun-Ru Chien , Ying Xu , -Wen Pan , Grace Smith and Thomas Buchholz Economic Burden of Renal Cell Carcinoma in the US: Part II - An Updated Analysis pp. 331-341 Ya-Chen Shih , Chun-Ru Chien , Ying Xu , -Wen Pan , Grace Smith and Thomas Buchholz Bivalirudin: A Pharmacoeconomic Profile of its Use in Patients with Acute Coronary Syndromes pp. 343-359 Katherine Lyseng-Williamson Volume 29, issue 3 , 2011
Including Indirect Medical Care Costs from Survivor Years of Life in Economic Evaluations pp. 173-174 John Nyman and Hawre Jalal Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations pp. 175-187 Pieter van Baal , Albert Wong , Laurentius Slobbe , Johan Polder , Werner B.F. Brouwer and G. de Wit Sample Size and Power for Cost-Effectiveness Analysis (Part 1) pp. 189-198 Henry Glick Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children: A Review pp. 199-211 Chantal Boonacker , Pieter Broos , Elisabeth Sanders , Anne Schilder and Maroeska Rovers Advances in Cancer Therapeutics and Patient Access to New Drugs pp. 213-224 George Dranitsaris , Ilse Truter , Martie Lubbe , Eitan Amir and William Evans Value of Information in the Osteoarthritis Setting: Cost Effectiveness of COX-2 Selective Inhibitors, Traditional NSAIDs and Proton Pump Inhibitors pp. 225-237 Nicholas Latimer , Joanne Lord , Robert Grant , O'Mahony, Rachel , John Dickson and Philip Conaghan Comparing Methods of Data Synthesis: Re-Estimating Parameters of an Existing Probabilistic Cost-Effectiveness Model pp. 239-250 Mark Oppe , Maiwenn Al and Maureen Rutten-van Molken Posaconazole: A Pharmacoeconomic Review of its Use in the Prophylaxis of Invasive Fungal Disease in Immunocompromised Hosts pp. 251-268 Katherine Lyseng-Williamson Volume 29, issue 2 , 2011
Consistently Estimating Absolute Risk Difference when Translating Evidence to Jurisdictions of Interest pp. 87-96 Simon Eckermann , Michael Coory and Andrew Willan A Model to Transfer Trial-Based Pharmacoeconomic Analyses to Clinical Practice pp. 97-105 Afschin Gandjour Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration pp. 107-131 Paul Mitchell , Lieven Annemans , Richard White , Meghan Gallagher and Simu Thomas Febuxostat for the Management of Hyperuricaemia in Patients with Gout: A NICE Single Technology Appraisal pp. 133-140 Matt Stevenson and Abdullah Pandor A Systematic Review to Assess the Policy-Making Relevance of Dementia Cost-of-Illness Studies in the US and Canada pp. 141-156 Mark Oremus and S. Aguilar Impact of Treatment Success on Health Service Use and Cost in Depression: Longitudinal Database Analysis pp. 157-170 Sarah Byford , Barbara Barrett , Nicolas Despiégel and Alan Wade Volume 29, issue 1 , 2011
Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis pp. 1-15 Martin Hoyle Effects of Reference Pricing in Pharmaceutical Markets: A Review pp. 17-33 Matteo Maria Galizzi , Simone Ghislandi and Marisa Miraldo Calibrating Models in Economic Evaluation: A Seven-Step Approach pp. 35-49 Tazio Vanni , Jonathan Karnon , Jason Madan , Richard White , W. Edmunds , Anna Foss and Rosa Legood Calibrating Models in Economic Evaluation: A Comparison of Alternative Measures of Goodness of Fit, Parameter Search Strategies and Convergence Criteria pp. 51-62 Jonathan Karnon and Tazio Vanni Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and Chronic Myeloid Leukaemia pp. 63-82 Carl Rudolf Blankart , Tom Stargardt and Jonas Schreyögg Is There a Role for Pharmacoeconomics in Developing Countries? pp. 83-84 Asrul Shafie and Mohamed Hassali The Authors' Reply pp. 84-86 Zaheer-Ud-Din Babar and Shane Scahill
EconPapers is hosted by the
Örebro University School of Business.